Role of IL13RA2 in Sunitinib Resistance in Clear Cell Renal Cell Carcinoma.

Vascular endothelial growth factor (VEGF) and mammalian target of rapamycin are well-known therapeutic targets for renal cell carcinoma (RCC). Sunitinib is an agent that targets VEGF receptors and is considered to be a standard treatment for metastatic or unresectable clear cell RCC (ccRCC). However...

Popoln opis

Bibliografske podrobnosti

Principais autores:	Noboru Shibasaki, Toshinari Yamasaki, Toru Kanno, Ryuichiro Arakaki, Hiromasa Sakamoto, Noriaki Utsunomiya, Takahiro Inoue, Tatsuaki Tsuruyama, Eijiro Nakamura, Osamu Ogawa, Tomomi Kamba
Format:	Artigo
Jezik:	Inglês
Izdano:	Public Library of Science (PLoS) 2015-01-01
Serija:	PLoS ONE
Online dostop:	http://europepmc.org/articles/PMC4482605?pdf=render
Oznake:	Označite Brez oznak, prvi označite!